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Introduction: Fabry disease (FD) is a lysosomal storage disorder resulting in progressive nervous system, kidney
and heart disease. Enzyme replacement therapy (ERT) may halt or attenuate disease progression. Since
administration is burdensome and expensive, appropriate use is mandatory. We aimed to define European
consensus recommendations for the initiation and cessation of ERT in patients with FD.
Methods: A Delphi procedure was conducted with an online survey (n = 28) and a meeting (n = 15). Patient
organization representatives were present at the meeting to give their views. Recommendations were accepted
with ≥75% agreement and no disagreement.
Results: For classically affected males, consensus was achieved that ERT is recommended as soon as there are early
clinical signs of kidney, heart or brain involvement, but may be considered in patients of ≥16 years in the absence
of clinical signs or symptoms of organ involvement. Classically affected females and males with non-classical FD
should be treated as soon as there are early clinical signs of kidney, heart or brain involvement, while treatment
may be considered in females with non-classical FD with early clinical signs that are considered to be due to FD.
Consensus was achieved that treatment should not be withheld from patients with severe renal insufficiency
(GFR < 45 ml/min/1.73 m2) and from those on dialysis or with cognitive decline, but carefully considered on an
individual basis. Stopping ERT may be considered in patients with end stage FD or other co-morbidities, leading
to a life expectancy of <1 year. In those with cognitive decline of any cause, or lack of response for 1 year when
the sole indication for ERT is neuropathic pain, stopping ERT may be considered. Also, in patients with end stage
renal disease, without an option for renal transplantation, in combination with advanced heart failure (NYHA class IV),
cessation of ERT should be considered. ERT in patients who are non-compliant or fail to attend regularly at visits should
be stopped.
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Conclusion: The recommendations can be used as a benchmark for initiation and cessation of ERT, although final
decisions should be made on an individual basis. Future collaborative efforts are needed for optimization of these
recommendations.
Keywords: Fabry disease, Enzyme replacement therapy, Recommendations, Delphi procedureBackground
Diagnostic criteria and treatment options are often a
matter of debate and controversy, especially in the
field of rare diseases, such as Fabry disease (FD). The
European Fabry Working Group (EFWG) is an inde-
pendent organization of primarily physicians involved
in the treatment of FD throughout Europe. In this paper
we report the results generated by EFWG physicians,
with additional comments from patient representatives,
on consensus recommendations for initiation and cessa-
tion of enzyme replacement therapy (ERT) in FD.
Fabry disease
FD (McKusick 301500) is an X-linked multisystemic
lysosomal storage disorder with an estimated birth
prevalence of 1:40.000-170.000 [1-3]. Late onset forms
of the disease are more frequent [4]. The disease is
caused by a deficiency of the lysosomal hydrolase α-
galactosidase A (AGAL-A), resulting in storage of pri-
marily globotriaosylceramide (Gb3) [5,6]. More than 600
variants in the α-galactosidase A (GLA) gene have been
described, most of which appear in single families [1]. In
hemizygous males, the disease may present itself during
childhood or adolescence with characteristic features
such as neuropathic pain, hypo- or anhidrosis, dissemi-
nated angiokeratoma, cornea verticillata, and microalbu-
minuria. At a later age, progressive kidney disease,
hypertrophic cardiomyopathy and cerebrovascular dis-
ease (including stroke) can occur. This disease pheno-
type is currently reported as classical FD. Heterozygous
females may also be affected and generally demonstrate
a more variable and attenuated phenotype. In both males
and females, life expectancy is diminished, although this
is more apparent in males [7,8].
Substantial intrafamilial and interfamilial variability
in age of disease onset and disease progression exists
[9]. In the past five years, evidence has emerged that
some male patients with a proven disease causing
GLA gene mutation and reduced AGAL-A activity do
not express the complete set of signs and symptoms
as they occur in the cases with classical FD [1]. This
phenotype may be referred to as non-classical FD. Pa-
tients with non-classical FD may present with one sin-
gle non-specific symptom such as chronic kidney
disease or left ventricular hypertrophy (LVH). These
patients as well as female patients contribute significantlyto the phenotypical heterogeneity of FD. On the other
hand, the misclassification of some patients with a gen-
etic variant of unknown significance (GVUS) as Fabry
disease is an additional challenge [4] (see also Table 1),
which may result in inappropriate initiation of enzyme
treatment.
ERT with either agalsidase alfa or agasidase beta has
been developed for FD treatment. In 2001, both agalsi-
dases were authorized by the European Medicines
Agency “Under Exceptional Circumstances” which
means that it was deemed impossible for the applicant
to provide comprehensive data on the efficacy and safety
of the drug, since FD is very rare. Agalsidase alfa is au-
thorized at a dose of 0.2 mg/kg (Shire, Lexington, MA,
USA) and agalsidase beta at a dose of 0.3 - 1.0 mg/kg
(Genzyme, a Sanofi company, Cambridge, MA, USA).
No studies to date have shown convincing evidence on
clinical grounds for superiority or non-inferiority of ei-
ther one of these enzymes in head to head comparative
studies [10,11]. In general, ERT may decrease cardiac
mass [12-15] and reduce renal Gb3-accumulations
[16-18], while the effects on nervous system disease and
renal function are less well established [15,19-22]. In
addition, effects of treatment in patients with non-
classical FD are in general not studied separately and ob-
scure evaluation of outcomes. More recent studies have
focused on specific features, such as cardiac fibrosis or
severe renal dysfunction, which may compromise effect-
iveness of ERT, since the presence of these features
points to irreversible organ damage [17,19,23]. Based
upon these insights, early initiation of therapy is fre-
quently advocated. However, “early initiation of therapy”
has not been defined until now. In addition, it may be
questioned whether patients with end stage disease or
co-morbidities may still benefit from treatment. Several
local and national guidelines and protocols exist with
criteria to start ERT, some also defined stopping criteria
for ERT, but so far, no international consensus has been
obtained.
Methods
Patients
A diagnosis of FD can be challenging in individuals
with a GLA mutation in the absence of characteristic
phenotypic or biochemical FD features. For the pur-
pose of this consensus procedure, only patients with
Table 1 Diagnostic criteria for a definite diagnosis of FD
(adopted from Smid et al. with permission [24])
Definite diagnosis of FD
Males Females
GLA mutation GLA mutation
+ +
AGAL-A deficiency of ≤5% of mean
reference value in leukocytes
normal or deficient
AGAL-A in leukocytes
+ +
A or B or C
A
≥1 characteristic FD sign/symptom (Fabry neuropathic pain, cornea
verticillata or clustered angiokeratoma)*
B
an increase of plasma (lyso)Gb3 (within range of males with definite
FD diagnosis)
C
a family member with a definite FD diagnosis carrying the same
GLA mutation
Uncertain diagnosis of FD
Males/Females
All patients presenting with a non-specific FD sign (such as LVH,
stroke at young age, proteinuria) who do not fulfil the criteria for a
definite diagnosis of FD have a GLA GVUS. Further evaluations are
needed, following diagnostic algorithms**.
Gold standard for uncertain FD diagnoses
In subjects with an uncertain FD diagnosis, a GVUS and a non-specific
FD sign, the demonstration of characteristic storage in the affected
organ (e.g. heart, kidney, aside from skin) by electron microscopy
analysis, according to the judgment of an expert pathologist, in the
absence of medication that can lead to storage, confirms FD.
*Definitions:
Fabry neuropathic pain meets the ‘characteristic clinical criteria’ if there is
neuropathic pain in hands and/or feet, starting before age 18 years or
increasing with heat, fever. Quantitative sensory testing (QST) reveals a
decreased cold detection threshold and the intraepidermal nerve fiber density
is increased. There is no other cause for neuropathic pain.
Angiokeratoma meet the ‘characteristic clinical criteria’ if they are clustered
and present in characteristic areas: bathing trunk area, lips, and umbilicus.
There is no other cause for angiokeratoma.
Cornea verticillata meets the ‘characteristic clinical criteria’ if there is a whorl
like pattern of corneal opacities. There is no other cause (medication induced,
among other: Amiodarone, Chloroquine).
**For organ specific algorithms see Smid et al. [24] and Van der Tol et al. [41].
GLA mutation =mutation in the α-galactosidase A gene; AGAL-A = the lysosomal
hydrolase α-galactosidase A; FD = Fabry disease; Gb3 = globotriaosylceramide;
LVH = left ventricular hypertrophy; GVUS = genetic variant of unknown significance.
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ate study, diagnostic criteria have been addressed, see
Table 1 [24].
Consensus procedure
Physicians and researchers involved in daily care for FD
(n = 41) were invited to participate in the consensus
procedure and were asked to send local or national
documents with information on start and stop criteria
used in their country. Participating experts (n = 28) wereasked to disclose any conflicts of interests in writing
(see competing interests). A modified Delphi technique
was used to develop group consensus on start and stop
criteria for ERT in FD. For the first round, a background
document was compiled by the study team (MB, CHo)
with information on national and local treatment proto-
cols, an overview of inclusion and exclusion criteria ap-
plied in randomised controlled trials, and a summary of
studies that addressed the issue of limited effectiveness of
ERT in patients with renal or cardiac features potentially
influencing the outcome of ERT (for results of literature
review, see Additional file 1). Also, studies on the effects
of ERT on the brain (TIA/strokes, white matter lesions)
[12,19-23] and pain [25,26], and studies on the effective-
ness of ERT in children [27-32] were included, as well as
two studies on effects of antibodies [33,34]. Subsequently,
an online questionnaire was set up by the study team to
discuss initiation and cessation criteria. The panellists
were asked to assess criteria on a 5-point Likert scale
(1 = strongly disagree, 2 = disagree, 3 = neither agree nor
disagree, 4 = agree, 5 = strongly agree) and were invited
to add comments and suggestions. This survey was
followed by a face-to-face meeting with presentation
and discussion of anonymized results (absolute scores
and comments). Patient representatives from the Fabry
International Network (FIN) and the Fabry Support and
Information Group from the Netherlands (FSIGN) were
invited to participate in the discussions. After discus-
sion statements were modified if required, and panel-
lists voted again using the 5-point Likert scale. Final
recommendations were refined via a draft manuscript
on which panellists were asked to comment by email.
Statistical considerations
A criterion is used in the treatment recommendations
only if there was at least 75% agreement and no dis-
agreement (i.e. ≥75% of the panellists voted 1 or 2 while
none voted 4 or 5, and vice versa).
Results
Consensus panel
A list of physicians and researchers involved in daily care
for FD was prepared. This list consisted of 41 experts
who had expressed their interest in joining the EFWG or
who were known for their contributions to the field.
Twenty-eight (68%) responded to the online survey and
15 (37%) participated at the face-to-face meeting. Four
patient representatives from the FIN and FSIGN (CL,
LB, ASw, EM) attended the meeting and participated in
the discussions. All experts and patient representatives
gave their feedback on the draft manuscript, which was
subsequently amended according to their comments. All
experts finally agreed with the results presented in this
report.
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During the face-to-face meeting it was agreed to grade
the strength of recommendations according to the scale
as outlined in Table 2 [35] and statements were modified
according to this scale. It should be emphasized here
that the grading was primarily based on clinical experi-
ence, observational studies and a limited number of ran-
domised controlled trials that used mostly surrogate
endpoints.
Overall consensus
The online survey consisted of 57 statements. Thirty-
four (60%) of these 57 statements were discussed and
modified during the face-to face meeting, and one state-
ment was added, making a total of 58 statements of
which 35 (60%) were discussed during the meeting. A
statement was first formulated as a class I recommenda-
tion (i.e. “treatment with ERT is recommended” or “it is
recommended to stop treatment with ERT”) followed by
lower classes of recommendation (Classes IIA and IIB) if
there was no consensus. If no consensus was achieved
for a statement even when it was formulated as a Class
IIB recommendation (i.e. “treatment with ERT may be
considered” or “it may be considered to stop treat-
ment with ERT”), it was concluded that no consensus
could be achieved for that specific statement. Con-
sensus was achieved for 30 (86%) of these 35 state-
ments (see Additional file 2: Table S1 and Additional
file 3: Table S2). Six (10%) of the remaining 23 state-
ments were omitted as the group considered these
statements irrelevant, and 17 (29%) were either con-
sidered in the context of one of the other statements
or not discussed during the face-to-face meeting due
to time constraints.
Consensus criteria for initiation of ERT
The group agreed that a differentiation should be made
between male and female patients, and between patients
with classical and non-classical FD. The division of fe-
males into classical and non-classical FD is based on the
presence or absence of clustered angiokeratoma, cornea
verticillata, or a very high (lyso)Gb3 level. For males with
classical FD, consensus was achieved that treatment withTable 2 Classes of recommendation
Class I Evidence and/or general agreement that a given treatm
useful, effective
Class II Conflicting evidence and/or a divergence of opinion abo
the given treatment or procedure
Class IIA Weight of evidence/opinion is in favour of usefulness/ef
Class IIB usefulness/efficacy is less well established by evidence/o
Class III Evidence or general agreement that the given treatment o
and in some cases may be harmfulERT may be considered in patients of 16 years or older
even if they have no symptoms or clinical signs of organ
involvement (Class IIB recommendation). The diagnosis
of classical FD in these patients is based on the presence
of a GLA mutation, absent or very low residual enzyme
activity, and the presence of at least one of the following:
angiokeratoma, cornea verticillata, or a very high (lyso)
Gb3 level. Classically affected males and females and
males with non-classical FD should be treated as soon as
there are early signs of organ involvement (kidney, heart
and/or CNS signs) consistent with FD and not fully ex-
plained by other pathology (Class I recommendation),
while treatment may be considered in females with non-
classical FD and early clinical signs consistent with FD
(Class IIB recommendation). Organ specific criteria for
treatment initiation are depicted in Table 3.
The statement on hyperfiltration (GFR > 130 ml/min/
1.73 m2 corrected for age (>40 years: −1 ml/min/
1.73 m2/year [36])) as a reason to start ERT was omitted
because the clinical relevance of this finding was
considered unclear. Panellists agreed that treatment
should not be withheld in patients with severe renal
insufficiency (GFR < 45 ml/min/1.73 m2 corrected for age
(>40 years: −1 ml/min/1.73 m2/year)). Likewise, it was
agreed that treatment should not be withheld in patients
on dialysis even if they are not eligible for a renal trans-
plant, and in patients with cognitive decline of any cause.
Initiation or continuation treatment with ERT in these pa-
tients should be carefully considered on an individual basis.
It was emphasised that consent to treatment is needed,
preferably from the patient (Class I recommendations).
Consensus criteria to stop or not start ERT
Criteria to stop or not start ERT are summarized in
Table 4. These criteria apply to both male and female
patients with classical and non-classical disease except
for the criterion ‘lack of response when the sole indica-
tion for ERT is neuropathic pain’ which applies to all
but male patients with classical FD. This exception was
made since males with classical FD and neuropathic pain
are considered to be at high risk for developing clinical
signs of organ involvement within a short period of
time.ent or procedure is beneficial, Is recommended/is indicated
ut the usefulness/efficacy of
ficacy Should be considered
pinion May be considered
r procedure is not useful/effective, Is not recommended
Table 3 Consensus criteria for initiation of ERT
No signs or
symptoms
Renal* Cardiac* CNS* Pain* GI*
Classical FD, males if ≥ 16 years of
age (Class IIB)
- microalbuminuria† (Class I) - cardiac hypertrophy (MWT> 12 mm)
without (or only minimal signs of)
fibrosis (Class I)
- WMLs (Class IIB) - neuropathic pain (Class IIA) GI symptoms (Class IIA if
< 16 years of age, Class IIB
if > 16 years of age)- proteinuria
† (Class I) - TIA/stroke (Class IIA)
- renal insufficiency
(GFR 60–90)# (Class I) - signs of cardiac rhythm disturbances
$
(Class I)
- hearing loss, corrected
for age (Class IIB)
- neuropathic pain even if
completely controlled
(not interfering with daily
activities) with pain
medication (Class IIB)- renal insufficiency
(GFR 45–60)# (Class IIB)
Non-classical FD, males - microalbuminuria† (Class I) - cardiac hypertrophy (MWT> 12 mm)
without (or only minimal signs of)
fibrosis (Class I)
- WMLs (Class IIB) - neuropathic pain (Class IIA) GI symptoms (Class IIA if
< 16 years of age, Class
- proteinuria† (Class I) - TIA/stroke (Class IIA) - neuropathic pain even if
completely controlled
(not interfering with daily
activities) with pain
medication (Class IIB)
- renal insufficiency
(GFR 60–90)# (Class IIA)
- signs of cardiac rhythm disturbances$
(Class I)
- hearing loss, corrected
for age (Class IIB)
IIB if > 16 years of age)
- renal insufficiency
(GFR 45–60)# (Class IIB)
Classical FD, females - microalbuminuria†
(Class IIB)
- cardiac hypertrophy (MWT> 12 mm)
without (or only minimal signs of)
fibrosis (Class I)
- WMLs (Class IIB) - neuropathic pain (Class IIA) GI symptoms (Class IIA if
< 16 years of age, Class IIB
if > 16 years of age)
- proteinuria† (Class IIB)
- TIA/stroke (Class IIA) - neuropathic pain even if
completely controlled
(not interfering with daily
activities) with pain
medication (Class IIB)
- renal insufficiency
(GFR 60–90)# (Class IIA)
- hearing loss, corrected
for age (Class IIB)
- renal insufficiency
(GFR 45–60)# (Class IIB)
- signs of cardiac rhythm disturbances$
(Class I)
Non-classical FD, females - microalbuminuria†
(Class IIB)
- cardiac hypertrophy (MWT> 12 mm)
without (or only minimal signs of)
fibrosis (Class I)
- WMLs (Class IIB) - neuropathic pain (Class IIA) GI symptoms (Class IIA if
< 16 years of age, Class IIB
if > 16 years of age)
- proteinuria† (Class IIB)
- TIA/stroke (Class IIA) - neuropathic pain even if
completely controlled
(not interfering with daily
activities) with pain
medication (Class IIB)
- renal insufficiency
(GFR 60–90)# (Class IIB)
- hearing loss, corrected
for age (Class IIB)
- renal insufficiency
(GFR 45–60)# (Class IIB)
- signs of cardiac rhythm disturbances$
(Class I)
*consistent with FD and not fully explained by other pathology; †according to international guidelines of kidney disease, KDIGO criteria; #in ml/min/1.73 m2 corrected for age (>40 years: −1 ml/min/1.73 m2/year);
$sinus bradycardia, AF, repolarization disorders; ERT = enzyme replacement therapy; GFR = glomerular filtration rate; MWT =maximal wall thickness; CNS = central nervous system; WMLs = white matter lesions;
TIA = transient ischemic attack; GI = gastrointestinal.
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Table 4 Consensus criteria to stop or not start ERT
Stop criteria Class of recommendation
Non-compliance > 50% of infusions Class I
Failure to attend regularly (according to local guidelines) at FU visits Class I
Persistent life threatening or severe infusion reactions that do not respond to prophylaxis, e.g. anaphylaxis Class I
Patient request Class I
End stage renal disease, without an option for renal transplantation, in combination with advanced heart failure
(NYHA class IV)
Class IIA
End stage FD or other comorbidities with a life expectancy of < 1 year Class IIB
Severe cognitive decline of any cause Class IIB
Lack of response for 1 year when the sole indication for ERT is neuropathic pain while receiving maximum
supportive care*
Class IIB
Criteria for not starting ERT Class of recommendation
Advanced cardiac disease with extensive fibrosis [37] if cardiac disease is the sole treatment indication† Class I
End stage renal disease, without an option for renal transplantation, in combination with advanced heart failure
(NYHA class IV)
Class IIA
End stage FD or other comorbidities with a life expectancy of < 1 year Class IIB
Severe cognitive decline of any cause Class IIB
*does not apply to male patients with the classical phenotype; †consistent with FD and not fully explained by other pathology; ERT = enzyme replacement
therapy; FD = Fabry disease; FU = follow up; NYHA = New York Heart Association.
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cardiac indications (i.e. there are no other signs or symp-
toms for which treatment may be recommended) in FD
patients with advanced cardiac disease with extensive fi-
brosis [37] consistent with FD and not fully explained by
other pathology.
Statements for which no consensus was achieved
Additional file 4: Table S3 lists the statements for which
no consensus was achieved. The timing of initiation of
ERT in young males with classical FD without any symp-
toms or clinical signs of organ involvement was exten-
sively discussed among panellists. Although it was
agreed that treatment of these patients should not be
initiated at the age of 0–5 years, and that treatment may
be considered in patients of 16 years or older, some ad-
vocated for initiation of treatment at the age of 6–10
years (33%) or 11–15 years (47%).
There was no consensus on the statement that treat-
ment with ERT is recommended in patients with FD
with early signs of cardiac disease (unspecified), while
the panel agreed on more specific cardiac abnormal-
ities as criteria for initiation of ERT (see Table 3). In
addition, it was discussed whether podocyte storage as
shown on kidney biopsy as only sign of organ involve-
ment would be sufficient to start treatment with ERT.
Two-third disagreed while one-third neither agreed
nor disagreed.
Panellists did not agree on the statement that treat-
ment with ERT is not recommended for renal indication
in male patients with classical FD who have renalinsufficiency (GFR < 45 ml/min/1.73 m2 corrected for
age (>40 years: −1 ml/min/1.73 m2/year)). Forty percent
agreed with this statement, while 20% disagreed. The
remaining 40% neither agreed nor disagreed. Most
panellists (87%) agreed that treatment with ERT may
be considered in patients with severe renal insuffi-
ciency (GFR < 45 ml/min/1.73 m2 corrected for age
(>40 years: −1 ml/min/1.73 m2/year)). However, 1
panellist felt that renal function will deteriorate any-
way in these patients, and therefore no consensus was
achieved.
Specific items brought forward by patient representatives
Patient representatives expressed their concerns about
the statement to consider stopping treatment with
ERT in patients with FD and recurrent strokes. They
emphasised that these patients might still have good
quality of life and benefit from treatment in other
ways. It was therefore decided to omit this statement.
A similar consideration applies to patients with cogni-
tive decline. After discussion, consensus was achieved
that treatment should not be withheld in patients with
cognitive decline of any cause (including recurrent
strokes) while it was emphasised that consent to treat-
ment is needed, preferably from the patient (Class I
recommendation). In addition, it was agreed that stop-
ping treatment may be considered in patients with se-
vere cognitive decline (Class IIB recommendation) but
it was emphasised that cessation of ERT in these pa-
tients should be carefully considered on an individual
basis.
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stopped in patients who are non-compliant (missing >50%
of their infusions) or fail to attend regularly at visits (Class
I recommendations).
Discussion
Several national and local protocols exist with different
sets of criteria for the initiation and/or cessation of ERT
in FD. This divergence is mainly caused by the fact that
currently available evidence is limited. With the use of
an adapted Delphi procedure, a consensus panel consist-
ing of European FD experts deliberated the recommen-
dations for the initiation and cessation of ERT, reflecting
the current standard of evidence and practice. Com-
ments and suggestions from FD patient organization
representatives were also included.
We emphasise that our recommendations are only
applicable to patients with a definite diagnosis of FD ac-
cording to definitions provided in Table 1. This is of the
utmost importance to avoid initiation of ERT in individ-
uals without FD [4]. Our procedure resulted in separate
criteria for male and female patients, and for patients
with classical and non-classical FD. In general, initiation
of ERT is recommended as soon as there are early signs
of kidney, heart or brain involvement consistent with the
diagnosis of FD. For male patients with classical FD
treatment with ERT may even be considered before clin-
ical signs or symptoms are evident, whereas the recom-
mendation to start ERT in females with non-classical FD
and early clinical signs is less strong. Our recommenda-
tion to initiate ERT when early clinical signs of FD occur
is based on recent study reports showing that specific
features of advanced disease, such as cardiac fibrosis or
severe renal dysfunction, may compromise effectiveness
of ERT. The presence of these features may point to ir-
reversible organ damage [17,19,23]. Based upon these in-
sights, early initiation of therapy is advocated. During
the consensus procedure, however, it became clear that
panellists differed in what they considered early. Some
advocated starting treatment in classically affected males
between the ages of 6 to 10 years. They argued that from
a metabolic point of view ERT should be started as soon
as possible. However, others expressed their preference
to wait until the patient presents with signs or symptoms
of organ involvement, especially since data showing
benefit from starting ERT in the asymptomatic state are
still lacking. Moreover, the paediatricians in the group in
particular concurred in their view that early initiation of
ERT in asymptomatic children in the context of a very
slowly progressive disease is likely to interfere with nor-
mal childhood. It was finally agreed that initiation of
ERT may be considered (Class IIB recommendation) in
males with classical FD of 16 years or older even in the
absence of any signs or symptoms. It was emphasised,however, that by far most males with classical disease
will have signs or symptoms at the age of 16. With re-
spect to commencing treatment in classically affected
boys below the age of 16 years without clinical signs or
symptoms, the consensus recommendations may be up-
dated if new data supporting early treatment in children
becomes available (www.clinicaltrials.gov, study number
NCT00701415).
During the procedure, it was emphasised that having
signs of organ involvement is an indication to start ERT
only if organ damage is consistent with FD. All patients
should therefore undergo extensive clinical and bio-
chemical investigations, to map FD attributed organ
damage and to identify other causes of kidney, heart or
brain disease. This implies that in some cases a biopsy of
an affected organ is necessary. For instance, an endo-
myocardial biopsy should be considered in patients with
left ventricular hypertrophy as the sole presenting sign
of organ involvement, especially when the patient has
concomitant cardiovascular risk factors. Electron micro-
scopic examination of biopsy specimen allows identifica-
tion of other causes of organ damage. However, if
storage characteristic of FD is seen, the cardiac hyper-
trophy is at least in part related to FD, and ERT is
recommended.
Our recommendations assume that patients are receiv-
ing optimal supportive care. If ERT is started, angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II
receptor blockers (ARB) should be started or continued
according to the treatment guidelines for chronic kidney
disease (KDIGO) [38] and cardiovascular disease (ESC)
[39]. Antiplatelet therapy and statins are indicated if a
patient has suffered a stroke or transient ischemic attack
according to the AHA/ASA guidelines on prevention of
recurrent strokes [40]. Pain medication may be needed if a
patient has neuropathic pain.
The current recommendations are based on expert
opinion and knowledge emerging from observational
studies, since level A evidence (i.e. randomised con-
trolled trials data) is scarce. Further studies are war-
ranted to address effectiveness of ERT in patients with
various degrees of kidney, heart or brain involvement.
Panellists could, for example, not agree on a cut off
value below which GFR indicates irreversible kidney dis-
ease. Some argued that treatment with ERT is not rec-
ommended for renal indication if the GFR is below
45 ml/min/1.73 m2 corrected for age (>40 years: −1 ml/
min/1.73 m2/year), while others felt that there is still
much to be gained when the GFR is below 45 ml/min/
1.73 m2. So far, no studies have been reported that give
an unequivocal answer to this dilemma. In addition, it
was mentioned that the standard available follow-up
procedures differ between centres. For example, specific
cardiac magnetic resonance machines were used to detect
Biegstraaten et al. Orphanet Journal of Rare Diseases  (2015) 10:36 Page 8 of 10cardiac fibrosis [37]. Whether the results can be extrapo-
lated from one centre to others remains to be studied.
Conclusion
Our recommendations have to be interpreted in the
context of limited amount of evidence which implies
that they need to be reconsidered when clinically rele-
vant study results are published. Furthermore, the rec-
ommendations do not provide simple ‘go’ or a ‘no go’
rules; they should be used as a guidance for starting or
stopping ERT in a FD patient while final decisions
should be made on an individual basis taking into ac-
count FD features, concomitant diseases and personal
preferences. The EFWG has the intention to update the
recommendations on a regular basis and as such will act
as an independent source of guidance for those involved
in the care for patients with FD.
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